321 related articles for article (PubMed ID: 15585343)
1. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background.
Cabin DE; Gispert-Sanchez S; Murphy D; Auburger G; Myers RR; Nussbaum RL
Neurobiol Aging; 2005 Jan; 26(1):25-35. PubMed ID: 15585343
[TBL] [Abstract][Full Text] [Related]
2. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
4. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein.
Frasier M; Walzer M; McCarthy L; Magnuson D; Lee JM; Haas C; Kahle P; Wolozin B
Exp Neurol; 2005 Apr; 192(2):274-87. PubMed ID: 15755545
[TBL] [Abstract][Full Text] [Related]
5. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
6. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
[TBL] [Abstract][Full Text] [Related]
7. Gene dosage and pathogenesis of Parkinson's disease.
Eriksen JL; Przedborski S; Petrucelli L
Trends Mol Med; 2005 Mar; 11(3):91-6. PubMed ID: 15760766
[TBL] [Abstract][Full Text] [Related]
8. Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions.
Tsuchiya K; Tajima H; Kuwae T; Takeshima T; Nakano T; Tanaka M; Sunaga K; Fukuhara Y; Nakashima K; Ohama E; Mochizuki H; Mizuno Y; Katsube N; Ishitani R
Eur J Neurosci; 2005 Jan; 21(2):317-26. PubMed ID: 15673432
[TBL] [Abstract][Full Text] [Related]
9. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
Giasson BI; Duda JE; Quinn SM; Zhang B; Trojanowski JQ; Lee VM
Neuron; 2002 May; 34(4):521-33. PubMed ID: 12062037
[TBL] [Abstract][Full Text] [Related]
10. Aggregation of alpha-synuclein in the pathogenesis of Parkinson's disease.
Iwatsubo T
J Neurol; 2003 Oct; 250 Suppl 3():III11-4. PubMed ID: 14579119
[TBL] [Abstract][Full Text] [Related]
11. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.
Park JY; Lansbury PT
Biochemistry; 2003 Apr; 42(13):3696-700. PubMed ID: 12667059
[TBL] [Abstract][Full Text] [Related]
12. Threonine 53 in alpha-synuclein is conserved in long-living non-primate animals.
Larsen K; Hedegaard C; Bertelsen MF; Bendixen C
Biochem Biophys Res Commun; 2009 Sep; 387(3):602-5. PubMed ID: 19619507
[TBL] [Abstract][Full Text] [Related]
13. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
14. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
15. Selective noradrenergic vulnerability in α-synuclein transgenic mice.
Sotiriou E; Vassilatis DK; Vila M; Stefanis L
Neurobiol Aging; 2010 Dec; 31(12):2103-14. PubMed ID: 19152986
[TBL] [Abstract][Full Text] [Related]
16. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression.
Fan Y; Limprasert P; Murray IV; Smith AC; Lee VM; Trojanowski JQ; Sopher BL; La Spada AR
Hum Mol Genet; 2006 Oct; 15(20):3002-11. PubMed ID: 16959793
[TBL] [Abstract][Full Text] [Related]
17. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein.
Choi W; Zibaee S; Jakes R; Serpell LC; Davletov B; Crowther RA; Goedert M
FEBS Lett; 2004 Oct; 576(3):363-8. PubMed ID: 15498564
[TBL] [Abstract][Full Text] [Related]
18. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
19. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Volles MJ; Lansbury PT
Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
[TBL] [Abstract][Full Text] [Related]
20. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
Masliah E; Rockenstein E; Adame A; Alford M; Crews L; Hashimoto M; Seubert P; Lee M; Goldstein J; Chilcote T; Games D; Schenk D
Neuron; 2005 Jun; 46(6):857-68. PubMed ID: 15953415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]